- Home
- IBRX vs MLCO Comparison
IBRX vs MLCO Comparison
Compare IBRX & MLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- MLCO
- Stock Information
- Founded
- IBRX 2014
- MLCO 2004
- Country
- IBRX United States
- MLCO Hong Kong
- Employees
- IBRX N/A
- MLCO N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- MLCO Hotels/Resorts
- Sector
- IBRX Health Care
- MLCO Consumer Discretionary
- Exchange
- IBRX Nasdaq
- MLCO Nasdaq
- Market Cap
- IBRX 2.3B
- MLCO 2.5B
- IPO Year
- IBRX N/A
- MLCO 2006
- Fundamental
- Price
- IBRX $2.81
- MLCO $8.65
- Analyst Decision
- IBRX Strong Buy
- MLCO Buy
- Analyst Count
- IBRX 5
- MLCO 5
- Target Price
- IBRX $11.40
- MLCO $8.56
- AVG Volume (30 Days)
- IBRX 7.3M
- MLCO 4.3M
- Earning Date
- IBRX 08-11-2025
- MLCO 08-12-2025
- Dividend Yield
- IBRX N/A
- MLCO N/A
- EPS Growth
- IBRX N/A
- MLCO N/A
- EPS
- IBRX N/A
- MLCO 0.14
- Revenue
- IBRX $31,222,000.00
- MLCO $4,758,114,000.00
- Revenue This Year
- IBRX $567.98
- MLCO $7.26
- Revenue Next Year
- IBRX $160.56
- MLCO $5.97
- P/E Ratio
- IBRX N/A
- MLCO $61.06
- Revenue Growth
- IBRX 10238.41
- MLCO 14.07
- 52 Week Low
- IBRX $1.83
- MLCO $4.55
- 52 Week High
- IBRX $7.48
- MLCO $8.91
- Technical
- Relative Strength Index (RSI)
- IBRX 51.33
- MLCO 78.74
- Support Level
- IBRX $2.68
- MLCO $6.00
- Resistance Level
- IBRX $3.00
- MLCO $7.29
- Average True Range (ATR)
- IBRX 0.16
- MLCO 0.26
- MACD
- IBRX -0.00
- MLCO 0.13
- Stochastic Oscillator
- IBRX 62.00
- MLCO 89.49
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About MLCO Melco Resorts & Entertainment Limited
Melco Resorts and Entertainment Ltd is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 81% from Macao with the rest largely from the Philippines as of 2024.